drugset / Trial / NCT00581035

Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time

NCT00581035

Phase 4 Completed 712 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants

Timeline

Start
2006-01
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Meningitec Vaccine
Subject Prevnar 13 Vaccine

Indications

No indication recorded.